Chen Yu, M.D., M.B.A. is a Managing Partner who joined Vivo in 2004. Dr. Yu has extensive operating experience in a broad array of industries with stints at China KangHui, aQuantive, Eli Lilly, and Bain & Co. Most recently, as Chief Business Officer at KangHui (KH), he helped take the company public on the New York Stock Exchange in the most successful healthcare IPO of 2010. At Vivo, his interest is in both medical device and pharmaceutical companies and he currently serves on the boards of several life science companies, including Sagent Pharmaceuticals (SGNT), KSPC Pharmaceuticals (a Chinese joint venture with Sagent Pharmaceuticals and KangHong Pharmaceuticals), Rempex, Nora Therapeutics, and Synaptic Medical, a China based medical device company. Other investments include Achillion (ACHN), Cubist (CBST), and Tranzyme (TZYM). Dr. Yu is also a member of the Stanford Medical School Alumni Board of Governors. Dr. Yu received his M.D. and M.B.A. from Stanford University and graduated magna cum laude with a B.A. in Biology from Harvard University.